GO40558
10 Dec 2020
Trial Summary
This study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes (PROs) of RO7198457 plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma.
Acronym:
GO40558
ACTRN/NCT /ethics:
NCT03815058
Scientific title:
A study to evaluate the efficacy and safety of RO7198457 in combination with pembrolizumab versus pembrolizumab alone in participants with previously untreated advanced melanoma.
Sponsor / Cooperative group:
Genentech Inc.
Trial & Patient Characteristics
| Cancer Type | Melanoma & other skin |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | Advanced melanoma |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | 2019-01-08 |
| Anticipated End Date | 2022-09-01 |
Participating Hospitals
| Hospital | The Queen Elizabeth Hospital |
|---|---|
| Clinical Trial Coordinator | Pamela Cooper |
| pamela.cooper@sa.gov.au | |
| Phone | 08 8222 6140 |
| Principal Investigator | Dr Rachel Roberts-Thomson |
| Recruitment Status | Recruiting |